Background: Gait dysfunction is a common symptom of Parkinson's disease that can cause significant disability and put patients at risk for falls. These symptoms show variable responsiveness to dopaminergic therapy. Objective: To determine whether dopaminergic (rs1076560 DRD2 G > T and rs4680 catechole-o-methyltranspherase (COMT) Val158Met) or brain derived neurotrophic factor (rs6265 BDNF Val66Met) genetic polymorphisms are associated with gait function and medication responsiveness in Parkinson's disease. Method: Gait function was evaluated on two days for patients (ON and OFF medication in a counterbalanced fashion) and a single session for controls. Investigators were blinded to genotype during data collection. Associations between genotype and medication responsiveness were analyzed using mixed model ANOVAs. A priori hypotheses were tested using GAITRite ® electronic mat spatiotemporal gait parameters including step length, step width, velocity, portion of double and single support per gait cycle, and variability of these measures ON and OFF medication. Results: We found that the DRD2 polymorphism, but neither COMT nor BDNF, was consistently associated with gait function and medication responsiveness in the patients. Specifically, Parkinson's disease patients with reduced striatal D2 expression (DRD2 T allele carriers) had worse gait dysfunction and showed greater dopamine responsiveness of gait function compared to patients who were homozygous for the G allele. There was no effect of any of the genetic polymorphisms on gait for controls.
Parkinson's disease Gait Individual/subgroup differences DRD2 Dopaminergic medication responsiveness a b s t r a c t Background: Gait dysfunction is a common symptom of Parkinson's disease that can cause significant disability and put patients at risk for falls. These symptoms show variable responsiveness to dopaminergic therapy. Objective: To determine whether dopaminergic (rs1076560 DRD2 G > T and rs4680 catechole-o-methyltranspherase (COMT) Val158Met) or brain derived neurotrophic factor (rs6265 BDNF Val66Met) genetic polymorphisms are associated with gait function and medication responsiveness in Parkinson's disease. Method: Gait function was evaluated on two days for patients (ON and OFF medication in a counterbalanced fashion) and a single session for controls. Investigators were blinded to genotype during data collection. Associations between genotype and medication responsiveness were analyzed using mixed model ANOVAs. A priori hypotheses were tested using GAITRite ® electronic mat spatiotemporal gait parameters including step length, step width, velocity, portion of double and single support per gait cycle, and variability of these measures ON and OFF medication. Results: We found that the DRD2 polymorphism, but neither COMT nor BDNF, was consistently associated with gait function and medication responsiveness in the patients. Specifically, Parkinson's disease patients with reduced striatal D2 expression (DRD2 T allele carriers) had worse gait dysfunction and showed greater dopamine responsiveness of gait function compared to patients who were homozygous for the G allele. There was no effect of any of the genetic polymorphisms on gait for controls.
Conclusions and relevance:
The findings suggest that genetic subgrouping, in particular for DRD2, may be used to identify Parkinson's disease patient subgroups that are more dopamine responsive for gait function. © 2017 Elsevier Ltd. All rights reserved.
Introduction
Gait dysfunction in Parkinson's disease is characterized by slow, shuffling steps, postural changes and reduced arm swing. These symptoms present early in the disease, increase risk for falls, and potentially cause significant disability We previously reported that the single nucleotide polymorphism (SNP) rs1076560 in the dopamine D2 receptor (DRD2) gene is associated with the magnitude of L-DOPA improvements in motor sequence learning in Parkinson's disease patients; L-DOPA improved learning only in patients carrying the minor T allele [5] . These findings have potential implications for clinical treatment decisions, but genetic associations with L-DOPA responsiveness for more clinically relevant behaviors such as locomotion have been evaluated in only one study. This study found that genotype for the dopamine transporter gene SLC6A3 was associated with Unified Parkinson's Disease Rating Scale (UPDRS) motor score and gait responsiveness to both an acute L-DOPA challenge and 90 days of methylphenidate treatment [6] . These patients were all implanted with deep brain stimulators, however, raising the question of whether less severely affected patients would also show similar gene-medication associations.
In the current study, we evaluated whether the genetic polymorphisms COMT Val158Met (rs4680), DRD2 G > T (rs1076560) and BDNF Val66Met (rs6265) would predict medication responsiveness of gait function in Parkinson's disease. The COMT SNP (rs4680) regulates dopamine availability in the prefrontal cortex and corticostriatal circuits [7] . A substitution of the valine (Val) with methionine (Met) allele at this codon reduces COMT enzymatic activity, resulting in higher prefrontal dopamine availability [8] .
COMT genotype has been associated with gait speed in healthy older adults [9] . The DRD2 G > T polymorphism (rs1076560) influences dopamine availability by regulating striatal dopamine receptor expression. Healthy T allele carriersdwho have reduced D2 receptor expressiondoften perform worse on cognitive and motor tasks [10, 11] . We also evaluated the BDNF Val66Met polymorphism (rs6265) that regulates BDNF secretion. Met allele carriers frequently show reduced short-term brain plasticity and worse performance on motor learning tasks [12] . Moreover, BDNF protein is associated with dopamine release and uptake in vitro [13, 14] .
Here, we analyzed gait parameters in Parkinson's disease patients, both ON and OFF antiparkinsonian medication, and controls. We evaluated the association between the genetic variants COMT Val158Met (rs4680), DRD2 G > T (rs1076560) and BDNF Val66Met (rs6265) and Parkinson's disease gait dysfunction and medication responsiveness.
Materials and methods

Experimental design
We tested the effects of antiparkinsonian medications on gait parameters while patients walked at their fastest, preferred, and slowest speeds. For clinical relevance, we present only the preferred walking speed data but results for the other conditions were qualitatively similar. We evaluated whether medication responsiveness of gait parameters was associated with genotype for the COMT Val158Met, DRD2 G > T, and BDNF genetic polymorphisms.
Participants
Thirty-nine Parkinson's disease patients and 30 healthy volunteers participated. We excluded participants with known neurological or psychiatric diseases other than Parkinson's disease, who were not taking dopaminergic antiparkinsonian medication(s) or who had undergone surgery for deep brain stimulation.
A Gait data from four patients were removed from analyses due to: MOCA scores suggestive of dementia [n ¼ one; 17], a recent medication change (<six months; n ¼ one), a recent knee surgery (n ¼ one), and abnormal neurological findings on examination (n ¼ one). Analyses were performed on the remaining data from 36 patients (10 females) and 29 controls (16 females). Two control participants declined to consent to genotyping and were not included in the genotype analyses.
Genotyping
We obtained saliva samples using an Oragene DNA selfcollection kit. Genotyping was performed using a polymerase chain reaction following previously published protocols [11] . The SNPs for rs4680, rs1076560 and rs6265 were determined. The distributions of individuals within each genotype group are presented in esupp Table 1 ; these were in accord with an exact test of the Hardy-Weinberg equilibrium [ps > .09; 18].
Apparatus
We used a GAITRite ® electronic mat to collect gait parameters (CIR Systems, Inc., Sparta, NJ) using GAITRite ® Software (Version 
